8-K current report · filed Nov 5, 2026

Cryoport, Inc. (CYRX) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1CYRX overview

Short answer

Cryoport, Inc. (CYRX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Cryoport announced financial results for Q3 ended September 30, 2026.

Cryoport, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Cryoport announced financial results for Q3 ended September 30, 2026
  • Investors should review Exhibit 99.1 for reported revenue, profitability, cash flow and management outlook

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $50.2M, up 14%, led by Life Sciences Services growth of 18% and BioStorage/BioServices growth of 25%
  • Commercial cell and gene therapy revenue increased 20%, with support for 23 approved therapies and 788 clinical trials
  • Adjusted EBITDA turned positive at $1.1M versus negative $0.6M, but GAAP net loss widened to $10.9M
  • Total gross margin declined to 47.5% from 48.2%, driven by Products margin falling to 43.6% from 46.4%
  • Full-year 2026 revenue guidance raised to $197M-$199M, supported by 9M revenue of $147.0M, up 12%

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cryoport, Inc. 8-K filings

Get the next CYRX 8-K as it lands

Follow CYRX for push alerts, or ask the research agent what this filing means.